Osama Mosalem, MD (@osamamosalemmd) 's Twitter Profile
Osama Mosalem, MD

@osamamosalemmd

Hematology Oncology fellow @MayoClinic Florida, @michiganstateU @msu_medicine @CairoUniversity alumni. Father and Husband 🧑‍🧑‍🧒‍🧒🇺🇸🇪🇬

ID: 1311112239097753601

calendar_today30-09-2020 01:15:15

289 Tweet

648 Followers

447 Following

Thor Halfdanarson (@oncothor) 's Twitter Profile Photo

One of my imaging workhorses in the NET clinic, the CT enterography (CTE). Nothing better to visualize small NETs in the ileum. This patient has at least 30 small lesions that have been stable over many years and monitored with annual CTE. 50% or more of sbNETs are multifocal.

One of my imaging workhorses in the NET clinic, the CT enterography (CTE). Nothing better to visualize small NETs in the ileum. This patient has at least 30 small lesions that have been stable over many years and monitored with annual CTE. 50% or more of sbNETs are multifocal.
Yakup Ergün (@dr_yakupergun) 's Twitter Profile Photo

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer 2y PFS➡️72% vs 14% 💥When the right drug is given to the right patient at the right time, the survival curves can be as perfect as the one below👇 nejm.org/doi/full/10.10…

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

2y PFS➡️72% vs 14%

💥When the right drug is given to the right patient at the right time, the survival curves can be as perfect as the one below👇

nejm.org/doi/full/10.10…
Arndt Vogel (@arndtvogel) 's Twitter Profile Photo

Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types JCO Precision Oncology doi.org/10.1200/PO-24-… ❓How do identify dMMR pts 👉33.8% pts with MMR mutations have MMR loss 👉only 34% of pts with MMR loss had MMR mutations 👉we need both NGS & IHC testing❗️ ESMO - Eur. Oncology

Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types
<a href="/JCOPO_ASCO/">JCO Precision Oncology</a> 
doi.org/10.1200/PO-24-…
❓How do identify dMMR pts
👉33.8% pts with MMR mutations have MMR loss
👉only 34% of pts with MMR loss had MMR mutations
👉we need both NGS &amp; IHC testing❗️
<a href="/myESMO/">ESMO - Eur. Oncology</a>
Michael Shusterman, MD (@guildsman) 's Twitter Profile Photo

GI Oncology standard regimen doses remain too high for many real world patients. Retrospective and prospective trials demonstrating benefit of reduced doses or dose escalation are accumulating. #meded #gionc #crcsm #pancsm

Arndt Vogel (@arndtvogel) 's Twitter Profile Photo

Comparison of 1st chemotherapy in unresectable locally advanced or metastatic #PDAC The Lancet Oncology doi.org/10.1016/S1470-… 🔎systematic review & Bayesian network meta-analysis, 79 trials, 22 168 pts 👉NALIRIFOX & FOLFIRINOX may be the preferred options if feasible ESMO - Eur. Oncology

Comparison of 1st chemotherapy in unresectable locally advanced or metastatic #PDAC
<a href="/TheLancetOncol/">The Lancet Oncology</a> 
doi.org/10.1016/S1470-…
🔎systematic review &amp; Bayesian network meta-analysis, 79 trials, 22 168 pts
👉NALIRIFOX &amp; FOLFIRINOX may be the preferred options if feasible
<a href="/myESMO/">ESMO - Eur. Oncology</a>
Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo

HCC 101! For the longest time, HCC was a bit of a blackbox to me. So for today’s ROVER presentation, I started off with a 5-slide summary of HCC basics: a 20,000 foot overview. Sharing here. Short thread 🧵 1/6.

HCC 101!

For the longest time, HCC was a bit of a blackbox to me.

So for today’s ROVER presentation, I started off with a 5-slide summary of HCC basics: a 20,000 foot overview.

Sharing here. Short thread 🧵 1/6.
Pashtoon Kasi MD, MS (@pashtoonkasi) 's Twitter Profile Photo

#GI25 More about the immunotherapy BOT/BAL.🙌🏽 ✔️Neoadjuvant: 1️⃣🪺NEST➡️BOT/BAL 2️⃣🦄 UNICORN➡️BOT➕/➖BAL ✔️Metastatic: Dr. Marwan G. Fakih City of Hope 3️⃣BOT➕/➖BAL ➕Combinations 4️⃣FOLFOX-3B (BEV+BOT+BAL) 5️⃣iNKT🔵+RAM+TAX+ BOT+BAL Colorectal Cancer Alliance 2024 Advancements OncoAlert ASCO #CRCSM

#GI25 More about the immunotherapy BOT/BAL.🙌🏽

✔️Neoadjuvant:
1️⃣🪺NEST➡️BOT/BAL
2️⃣🦄 UNICORN➡️BOT➕/➖BAL

✔️Metastatic: <a href="/mgfakih/">Dr. Marwan G. Fakih</a> <a href="/cityofhope/">City of Hope</a> 
3️⃣BOT➕/➖BAL

➕Combinations
4️⃣FOLFOX-3B (BEV+BOT+BAL)
5️⃣iNKT🔵+RAM+TAX+ BOT+BAL

<a href="/CCAlliance/">Colorectal Cancer Alliance</a> 2024 Advancements

<a href="/OncoAlert/">OncoAlert</a> <a href="/ASCO/">ASCO</a> #CRCSM
Ibrahim Halil SAHIN, MD (@ibrahimsahinmd1) 's Twitter Profile Photo

✳️”Low sugar diet” question comes up in daily practice frequently as it is believed that “sugar feeds cancer”❗️ ✳️It is so important to differentiate “cancer prevention” and “treatment of advanced stage cancer” and they are highly different process; with distinct molecular &

Oncology Brothers (@oncbrothers) 's Twitter Profile Photo

We are excited to share a few upcoming live events in 2025 that we are moderating to discuss the current SoC, new data, conference highlights and board prep! 📅 Jan 24 #GI25 AIO, San Fran ✅ Register: bit.ly/aiogi25 📅 Feb 12 #GU25 AIO, San Fran ✅ Register:

We are excited to share a few upcoming live events in 2025 that we are moderating to discuss the current SoC, new data, conference highlights and board prep! 

📅 Jan 24 #GI25 AIO, San Fran 
✅ Register: bit.ly/aiogi25

📅 Feb 12 #GU25 AIO, San Fran
✅ Register:
Pashtoon Kasi MD, MS (@pashtoonkasi) 's Twitter Profile Photo

#GI25 an option for our patients with #BRAFV600E🧬 mutant colorectal cancer. Median OS not reached 🆚 14 months in the standard of care. HR=0.47! OncoAlert Chemo➕targeted therapy frontline. Both response rates & OS are meaningful.

#GI25 an option for our patients with #BRAFV600E🧬 mutant colorectal cancer.

Median OS not reached 🆚 14 months in the standard of care. HR=0.47!

<a href="/OncoAlert/">OncoAlert</a> 

Chemo➕targeted therapy frontline. 

Both response rates &amp; OS are meaningful.
Thor Halfdanarson (@oncothor) 's Twitter Profile Photo

Masterclass presentation on the management of advanced colorectal cancer from Tanios Bekaii-Saab, MD at the inaugural Mayo Clinic Heme/Onc Board Review and Practice Update conference this week. Can he fit it in one slide...? He sure can! Don't miss this next year. tinyurl.com/rh7c927c

Masterclass presentation on the management of advanced colorectal cancer from <a href="/GIcancerDoc/">Tanios Bekaii-Saab, MD</a> at the inaugural Mayo Clinic Heme/Onc Board Review and Practice Update conference this week. Can he fit it in one slide...? He sure can! 

Don't miss this next year. tinyurl.com/rh7c927c
Mrinal Patnaik (@mrinalpatnaik) 's Twitter Profile Photo

Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific membrane antigen therapy pubmed.ncbi.nlm.nih.gov/40176753/ #Lutetium #CH #PPM1D #TP53 #prostate yael kusne MD PhD Mayo Clinic Comprehensive Cancer Center

Vivek Subbiah, MD (@viveksubbiah) 's Twitter Profile Photo

🚨 Hot off the press! 🚨 The ESMO - Eur. Oncology Precision Oncology Working Group, led by the amazing Ben Westphalen G Curigliano MD PhD has unveiled key "Recommendations for structuring Molecular Tumour Boards (MTBs) in clinical practice", now published in ESMO's flagship journal Annals of Oncology

🚨 Hot off the press! 🚨 The <a href="/myESMO/">ESMO - Eur. Oncology</a>  Precision Oncology Working Group, led by the amazing <a href="/BenWestphalen/">Ben Westphalen</a> <a href="/curijoey/">G Curigliano MD PhD</a>  has unveiled key "Recommendations for structuring Molecular Tumour Boards (MTBs) in clinical practice", now published in ESMO's flagship journal <a href="/Annals_Oncology/">Annals of Oncology</a>
Nicholas Hornstein (@gimedonc) 's Twitter Profile Photo

I know it has probably made its way into clinical practice (at least it has for me), but Ipi-Nivo now has FDA approval based on CheckMate8HW for dMMR mCRC! Excited to have this for our patients! Key Points: Ipi (1mg/kg) + Nivo (240mg) Q3W for 4 cycles then Nivo alone Massive

I know it has probably made its way into clinical practice (at least it has for me), but Ipi-Nivo now has FDA approval based on CheckMate8HW for dMMR mCRC! 

Excited to have this for our patients! 

Key Points:
Ipi (1mg/kg) + Nivo (240mg) Q3W for 4 cycles then Nivo alone 
Massive
Julie Hallet (@halletjulie) 's Twitter Profile Photo

🦓 NANETS is going to LA ⭐️🍿🎥 If you’re around and want to learn more about #NETs, join us! I’ll be there along with Thor Halfdanarson Callisia Clarke MD Jess Maxwell MD MBA Laleh Melstrom & many more 📆 May 17 🔗 nanets.net/component/civi… Thanks Alexandra Gangi, MD for organizing!

🦓 <a href="/NANETS1/">NANETS</a> is going to LA ⭐️🍿🎥

If you’re around and want to learn more about #NETs, join us! I’ll be there along with <a href="/OncoThor/">Thor Halfdanarson</a> <a href="/DrCNClarke/">Callisia Clarke MD</a> <a href="/JMaxCutsNETs/">Jess Maxwell MD MBA</a> <a href="/laleh_melstrom/">Laleh Melstrom</a> &amp; many more 

📆 May 17
🔗 nanets.net/component/civi…

Thanks <a href="/AGangiMD/">Alexandra Gangi, MD</a> for organizing!
Osama Mosalem, MD (@osamamosalemmd) 's Twitter Profile Photo

Big week for #GIcancers, Nivo + Ipi gets FDA approved for HCC #livercancer, just a few days after the same regimen got approval in MSI-H #coloncancer. #CheckMate9DW ascopubs.org/doi/10.1200/JC… #Chekmate8HW nejm.org/doi/full/10.10… OncoAlert Oncology Brothers OncLive.com GI Oncology Now

Big week for #GIcancers, Nivo + Ipi gets <a href="/FDA/">FDA</a> approved for HCC #livercancer, just a few days after the same regimen got approval in MSI-H #coloncancer. #CheckMate9DW ascopubs.org/doi/10.1200/JC…

#Chekmate8HW nejm.org/doi/full/10.10…
<a href="/OncoAlert/">OncoAlert</a> <a href="/OncBrothers/">Oncology Brothers</a> <a href="/OncLive/">OncLive.com</a> <a href="/GiOncNow/">GI Oncology Now</a>
Erman Akkus (@erman_akkus) 's Twitter Profile Photo

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations | Revolution Medicines #ESMOGI25 ir.revmed.com/news-releases/…